CoChat
Sign Up
Cited by 276Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments

Neuroinflammation in Alzheimer’s disease

Open access
Zhang, Fengjin, Jiang, LinLan·2015·Neuropsychiatric Disease and Treatment
DOI 10.2147/ndt.s75546PMC PMC4321665
Open this paper in CoChat — free accountOpen PDF

Abstract

Amyloid-β plaques and neurofibrillary tangles are the main neuropathological hallmarks in Alzheimer's disease (AD), the most common cause of dementia in the elderly. However, it has become increasingly apparent that neuroinflammation plays a significant role in the pathophysiology of AD. This review summarizes the current status of neuroinflammation research related to AD, focusing on the connections between neuroinflammation and some inflammation factors in AD. Among these connections, we discuss the dysfunctional blood-brain barrier and alterations in the functional responses of microglia and astrocytes in this process. In addition, we summarize and discuss the role of intracellular signaling pathways involved in inflammatory responses in astrocytes and microglia, including the mitogen-activated protein kinase pathways, nuclear factor-kappa B cascade, and peroxisome proliferator-activated receptor-gamma transcription factors. Finally, the dysregulation of the control and release of pro- and anti-inflammatory cytokines and classic AD pathology (amyloid plaques and neurofibrillary tangles) in AD is also reviewed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ndt.s75546

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The Alzheimer's disease brain contains more complex pathology that is highly related to neuroinflammation.

    “Other than the neurotoxicity of Aβ aggregates, the AD brain contains more complex pathology, which is highly related to neuroinflammation.23, 43”

    From Acoustofluidic assembly of 3D neurospheroids to model Alzheimer's disease (2020) · cites this paper as [43]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 191 · Cited by 276

Research works printed but not linked: 155

  1. [2]Hensley K Neuroinflammation in Alzheimer’s disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation J Alzheimers Dis 2010 21 1 1 14 20182045 PMC3792565
  2. [3]McGeer EG McGeer PL Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy J Alzheimer Dis 2010 19 1 355 361 20061650
  3. [4]Brown GC Bal-Price A Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria Mol Neurobiol 2003 27 3 325 355 12845153
  4. [5]Arima Y Kamimura D Sabharwal L Regulation of immune cell infiltration into the CNS by regional neural Inputs explained by the gate theory Mediators Inflamm 2013 2013 898165 23990699 PMC3748732
  5. [7]Maeda T Kanda T Blood–brain barrier and blood-nerve barrier in neuroinflammatory diseases Nippon Rinsho 2013 71 5 789 794 23777083
  6. [8]Syvanen S Eriksson J Advances in PET imaging of P-glycoprotein function at the blood–brain barrier ACS Chem Neurosci 2013 4 2 225 237 23421673 PMC3582299
  7. [9]Gheorghiu M Enciu A-M Popescu BO Gheorghiu E Functional and molecular characterization of the effect of amyloid-beta(42) on an in vitro epithelial barrier model J Alzheimers Dis 2014 38 4 787 798 24072066
  8. [10]Burgmans S van de Haar HJ Verhey FRJ Backes WH Amyloid-beta interacts with blood–brain barrier function in dementia: a systematic review J Alzheimers Dis 2013 35 4 859 873 23542866
  9. [11]Steinman L Inflammatory cytokines at the summits of pathological signal cascades in brain diseases Sci Signal 2013 6 258 e3 23322904
  10. [13]Rivest S Lacroix S Vallières L Nadeau S Zhang J Laflamme N How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli Proc Soc Exp Biol Med 2000 223 1 22 38 10632958
  11. [17]Heneka MT O’Banion MK Inflammatory processes in Alzheimer’s disease J Neuroimmunol 2007 184 1 69 91 17222916
  12. [18]Czeh M Gressens P Kaindl AM The yin and yang of microglia Dev Neurosci 2011 33 3–4 199 209 21757877
  13. [20]Glass CK Saijo K Winner B Marchetto MC Gage FH Mechanisms underlying inflammation in neurodegeneration Cell 2010 140 6 918 934 20303880 PMC2873093
  14. [24]Morales I Jimenez JM Mancilla M Maccioni RB Tau oligomers and fibrils induce activation of microglial cells J Alzheimers Dis 2013 37 4 849 856 23948931
  15. [25]Rodriguez JJ Witton J Olabarria M Noristani HN Verkhratsky A Increase in the density of resting microglia precedes neuritic plaque formation and microglial activation in a transgenic model of Alzheimer’s disease Cell Death Dis 2010 1 e1 21364611 PMC3032511
  16. [26]Griciuc A Serrano-Pozo A Parrado AR Alzheimer’s disease risk gene CD33 inhibits microglial uptake of amyloid beta Neuron 2013 78 4 631 643 23623698 PMC3706457
  17. [27]Scheffler K Stenzel J Krohn M Determination of spatial and temporal distribution of microglia by 230 nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of Alzheimer’s disease Curr Alzheimer Res 2011 8 7 781 788 21244350 PMC3117051
  18. [29]El Khoury J Hickman S Thomas C Loike J Silverstein S Microglia, scavenger receptors, and the pathogenesis of Alzheimer’s disease Neurobiol Aging 1998 19 1 S81 S84 9562474
  19. [30]Leissring MA Farris W Chang AY Enhanced proteolysis of β-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death Neuron 2003 40 6 1087 1093 14687544
  20. [31]Li W Poteet E Xie L Liu R Wen Y Yang S-H Regulation of matrix metalloproteinase 2 by oligomeric amyloid β protein Brain Res 2011 1387 141 148 21376707 PMC3075344
  21. [32]Liu B Hong J-S Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention J Pharmacol Exp Ther 2003 304 1 1 7 12490568
  22. [33]Naert G Rivest S The role of microglial cell subsets in Alzheimer’s disease Curr Alzheimer Res 2011 8 2 151 155 21418002
  23. [35]Floden AM Combs CK Microglia demonstrate age-dependent interaction with amyloid-beta fibrils J Alzheimers Dis 2011 25 2 279 293 21403390 PMC3295838
  24. [37]Hanisch UK Kettenmann H Microglia: active sensor and versatile effector cells in the normal and pathologic brain Nat Neurosci 2007 10 11 1387 1394 17965659
  25. [39]Sherwood CC Stimpson CD Raghanti MA Evolution of increased glia – neuron ratios in the human frontal cortex Proc Natl Acad Sci U S A 2006 103 37 13606 13611 16938869 PMC1564260
  26. [41]Molofsky AV Krencik R Ullian EM Astrocytes and disease: a neurodevelopmental perspective Genes Dev 2012 26 9 891 907 22549954 PMC3347787
  27. [42]Sun D Jakobs TC Structural remodeling of astrocytes in the injured CNS Neuroscientist 2012 18 6 567 588 21982954 PMC3713769
  28. [43]Sidoryk-Wegrzynowicz M Wegrzynowicz M Lee E Bowman AB Aschner M Role of astrocytes in brain function and disease Toxicol Pathol 2011 39 1 115 123 21075920 PMC6218934
  29. [45]Medeiros R LaFerla FM Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony Exp Neurol 2013 239 133 138 23063604
  30. [46]Crowe E Bhat R Bitto A Astrocyte senescence as a component of Alzheimer’s disease Exp Gerontol 2013 48 7 695 696 PMC3440417 22984612
  31. [47]Blasko I Veerhuis R Stampfer-Kountchev M Saurwein-Teissl M Eikelenboom P Grubeck-Loebenstein B Costimulatory effects of interferon-gamma and interleukin-1beta or tumor necrosis factor alpha on the synthesis of Abeta1–40 and Abeta1–42 by human astrocytes Neurobiol Dis 2000 7 6 pt B 682 689 11114266
  32. [48]Yu Y He J Zhang Y Increased hippocampal neurogenesis in the progressive stage of Alzheimer’s disease phenotype in an APP/PS1 double transgenic mouse model Hippocampus 2009 19 12 1247 1253 19309037
  33. [49]Tang BL Neuronal protein trafficking associated with Alzheimer disease: from APP and BACE1 to glutamate receptors Cell Adh Migr 2009 3 1 118 128 19372755 PMC2675158
  34. [50]Hartlage-Rübsamen M Zeitschel U Apelt J Astrocytic expression of the Alzheimer’s disease β-secretase (BACE1) is stimulus-dependent Glia 2003 41 2 169 179 12509807
  35. [51]Roßner S Lange-Dohna C Zeitschel U Perez-Polo JR Alzheimer’s disease β-secretase BACE1 is not a neuron-specific enzyme J Neuro-chem 2005 92 2 226 234 15663471
  36. [52]Weggen S Diehlmann A Buslei R Beyreuther K Bayer T Prominent expression of presenilin-1 in senile plaques and reactive astrocytes in Alzheimer’s disease brain Neuroreport 1998 9 14 3279 3283 9831464
  37. [53]Zhao J O’Connor T Vassar R The contribution of activated astrocytes to A beta production: implications for Alzheimer’s disease pathogenesis J Neuroinflammation 2011 2 8 PMC3216000 22047170
  38. [54]Miners JS Van Helmond Z Kehoe PG Love S Changes with age in the activities of β-secretase and the Aβ-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme Brain Pathol 2010 20 4 794 802 20175776 PMC8094798
  39. [55]Apelt J Ach K Schliebs R Aging-related down-regulation of neprilysin, a putative β-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of β-amyloid plaques Neurosci Lett 2003 339 3 183 186 12633883
  40. [56]Rossello XS Igbavboa U Weisman GA Sun GY Wood WG AP-2 beta regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes Brain Res 2012 1444 87 95 22325097 PMC3292686
  41. [57]Rossi D Volterra A Astrocytic dysfunction: insights on the role in neurodegeneration Brain Res Bull 2009 80 4 224 232 19631259
  42. [58]Qin H Benveniste EN ELISA methodology to quantify astrocyte production of cytokines/chemokines in vitro Methods Mol Biol 2012 2012 814 235 249 22144311
  43. [59]Talantova M Sanz-Blasco S Zhang X A beta induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss Proc Natl Acad Sci U S A 2013 110 27 E2518 E2527 23776240 PMC3704025
  44. [61]Thal DR The role of astrocytes in amyloid beta-protein toxicity and clearance Exp Neurol 2012 236 1 1 5 22575598
  45. [62]Furman JL Sama DM Gant JC Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer’s disease J Neurosci 2012 32 46 16129 16140 23152597 PMC3506017
  46. [63]Krishna M Narang H The complexity of mitogen-activated protein kinases (MAPKs) made simple Cell Mol Life Sci 2008 65 22 3525 3544 18668205 PMC11131782
  47. [64]Wang X Tournier C Regulation of cellular functions by the ERK5 signalling pathway Cell Signal 2006 18 6 753 760 16376520
  48. [65]Kyriakis JM Avruch J Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update Physiol Rev 2012 92 2 689 737 22535895
  49. [66]Gerits N Kostenko S Moens U In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice Transgenic Res 2007 16 3 281 314 17219248
  50. [67]Wagner EF Nebreda ÁR Signal integration by JNK and p38 MAPK pathways in cancer development Nat Rev Cancer 2009 9 8 537 549 19629069
  51. [68]Orejana L Barros-Minones L Aguirre N Puerta E Implication of JNK pathway on tau pathology and cognitive decline in a senescence-accelerated mouse model Exp Gerontol 2013 48 6 565 571 23501261
  52. [69]Sclip A Antoniou X Colombo A c-Jun N-terminal kinase regulates soluble A beta oligomers and cognitive impairment in AD mouse model J Biol Chem 2011 286 51 43871 43880 22033930 PMC3243502
  53. [70]Shoji M Iwakami N Takeuchi S JNK activation is associated with intracellular β-amyloid accumulation Mol Brain Res 2000 85 1 221 233 11146125
  54. [71]Lin W Ding M Xue J Leng W The role of TLR2/JNK/NF-kappa B pathway in amyloid beta peptide-induced inflammatory response in mouse NG108-15 neural cells Int Immunopharmacol 2013 17 3 880 884 24126115
  55. [72]Munoz L Ammit AJ Targeting p38 MAPK pathway for the treatment of Alzheimer’s disease Neuropharmacology 2010 58 3 561 568 19951717
  56. [73]Lee YB Schrader JW Kim SU p38 MAP kinase regulates TNF-α production in human astrocytes and microglia by multiple mechanisms Cytokine 2000 12 7 874 880 10880231
  57. [74]Xing B Xin T Hunter RL Bing G Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt J Neuroinflammation 2008 5 4 1 11 18205920 PMC2254610
  58. [75]Giovannini MG Scali C Prosperi C β-amyloid-induced inflammation and cholinergic hypofunction in the rat brain in vivo: involvement of the p38MAPK pathway Neurobiol Dis 2002 11 2 257 274 12505419
  59. [76]Matos M Augusto E Oliveira C Agostinho P Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: involvement of oxidative stress and mitogen-activated protein kinase cascades Neuroscience 2008 156 4 898 910 18790019
  60. [77]Pawate S Bhat NR C-Jun N-terminal kinase (JNK) regulation of iNOS expression in glial cells: predominant role of JNK1 isoform Antioxid Redox Signal 2006 8 5–6 903 909 16771680
  61. [78]Marcus JS Karackattu SL Fleegal MA Sumners C Cytokine-stimulated inducible nitric oxide synthase expression in astroglia: role of Erk mitogen-activated protein kinase and NF-κB Glia 2003 41 2 152 160 12509805
  62. [79]Han JE Choi JW Control of JNK for an activation of NADPH oxidase in LPS-stimulated BV2 microglia Arch Pharm Res 2012 35 4 709 715 22553064
  63. [80]Yenki P Khodagholi F Shaerzadeh F Inhibition of phosphorylation of JNK suppresses A beta-induced ER stress and upregulates pro-survival mitochondrial proteins in rat hippocampus J Mol Neurosci 2013 49 2 262 269 22706709
  64. [81]Lu D-Y Leung Y-M Su K-P Interferon-alpha induces nitric oxide synthase expression and haem oxygenase-1 down-regulation in microglia: implications of cellular mechanism of IFN-alpha-induced depression Int J Neuropsychopharmacol 2013 16 2 433 444 22717332
  65. [82]Xing B Bachstetter AD Van Eldik LJ Deficiency in p38beta MAPK fails to inhibit cytokine production or protect neurons against inflammatory insult in in vitro and in vivo mouse models PloS One 2013 8 2 e56852 e56852 23457629 PMC3574114
  66. [83]Chang L Jones Y Ellisman MH Goldstein LS Karin M JNK1 is required for maintenance of neuronal microtubules and controls phos-phorylation of microtubule-associated proteins Dev Cell 2003 4 4 521 533 12689591
  67. [84]Kelleher I Garwood C Hanger DP Anderton BH Noble W Kinase activities increase during the development of tauopathy in htau mice J Neurochem 2007 103 6 2256 2267 17908241
  68. [85]Lee JW Lee YK Ban JO Green tea (−)-epigallocatechin-3-gallate inhibits beta-amyloid-induced cognitive dysfunction through modification of secretase activity via inhibition of ERK and NF-kappa B pathways in mice J Nutr 2009 139 10 1987 1993 19656855
  69. [87]Jana M Dasgupta S Liu X Pahan K Regulation of tumor necrosis factor-α expression by CD40 ligation in BV-2 microglial cells J Neurochem 2002 80 1 197 206 11796758
  70. [88]Nakajima K Matsushita Y Tohyama Y Kohsaka S Kurihara T Differential suppression of endotoxin-inducible inflammatory cytokines by nuclear factor kappa B (NFκB) inhibitor in rat microglia Neurosci Lett 2006 401 3 199 202 16580131
  71. [89]Bhat NR Feinstein DL Shen Q Bhat AN p38 MAPK-mediated transcriptional activation of inducible nitric-oxide synthase in glial cells roles of nuclear factors, nuclear factor κB, cAMP response element-binding protein, CCAAT/enhance-binding protein-β, and activating transcription factor-2 J Biol Chem 2002 277 33 29584 29592 12048217
  72. [90]Dai Y-Q Jin D-Z Zhu X-Z Lei D-L Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes Neurosci Res 2006 55 2 154 160 16600409
  73. [91]Combs CK Johnson DE Karlo JC Cannady SB Landreth GE Inflammatory mechanisms in Alzheimer’s disease: inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists J Neurosci 2000 20 2 558 567 10632585 PMC6772401
  74. [92]Landreth G Jiang Q Mandrekar S Heneka M PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease Neurothera-peutics 2008 5 3 481 489 PMC2593876 18625459
  75. [93]Sen R Baltimore D Multiple nuclear factors interact with the immunoglobulin enhancer sequences Cell 1986 46 5 705 716 3091258
  76. [94]Hayden MS Ghosh S Shared principles in NF-κB signaling Cell 2008 132 3 344 362 18267068
  77. [95]Mincheva-Tasheva S Soler RM NF-κB signaling pathways role in nervous system physiology and pathology Neuroscientist 2013 19 2 175 194 22785105
  78. [96]Pugazhenthi S Zhang Y Bouchard R Mahaffey G Induction of an inflammatory loop by interleukin-1 beta and tumor necrosis factor-alpha involves NF-kappa B and STAT-1 in differentiated human neuroprogenitor cells PLoS One 2013 8 7 e69585 23922745 PMC3726669
  79. [97]Mir M Tolosa L Asensio VJ Lladó J Olmos G Complementary roles of tumor necrosis factor alpha and interferon gamma in inducible microglial nitric oxide generation J Neuroimmunol 2008 204 1 101 109 18703234
  80. [98]Koo JW Russo SJ Ferguson D Nestler EJ Duman RS Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior Proc Natl Acad Sci U S A 2010 107 6 2669 2674 20133768 PMC2823860
  81. [99]Yamamoto Y Gaynor RB Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer J Clin Invest 2001 107 2 135 142 11160126 PMC199180
  82. [100]Barger SW Mattson MP Induction of neuroprotective κB-dependent transcription by secreted forms of the Alzheimer’s β-amyloid precursor Mol Brain Res 1996 40 1 116 126 8840019
  83. [101]Buggia-Prevot V Sevalle J Rossner S Checler F NFκB-dependent control of BACE1 promoter transactivation by Aβ42 J Biol Chem 2008 283 15 10037 10047 18263584
  84. [102]Valerio A Boroni F Benarese M NF-κB pathway: a target for preventing β-amyloid (Aβ)-induced neuronal damage and Aβ42 production Eur J Neurosci 2006 23 7 1711 1720 16623827
  85. [104]Niu YL Zhang WJ Wu P Expression of the apoptosis-related proteins caspase-3 and NF-κB in the hippocampus of Tg2576 mice Neurosci Bull 2010 26 1 37 46 20101271 PMC5560375
  86. [105]Chami L Buggia-Prévot V Duplan E Nuclear factor-kappa B regulates beta APP and beta- and gamma-secretases differently at physiological and supraphysiological A beta concentrations J Biol Chem 2012 287 29 24573 24584 22654105 PMC3397882
  87. [106]Paris D Patel N Quadros A Inhibition of Aβ production by NF-κB inhibitors Neurosci Lett 2007 415 1 11 16 17223266
  88. [107]Sung S Yang H Uryu K Modulation of nuclear factor-κB activity by indomethacin influences Aβ levels but not Aβ precursor protein metabolism in a model of Alzheimer’s disease Am J Pathol 2004 165 6 2197 2206 15579461 PMC1618710
  89. [108]Ascolani A Balestrieri E Minutolo A Dysregulated NF-kappa B pathway in peripheral mononuclear cells of Alzheimer’s disease patients Curr Alzheimer Res 2012 9 1 128 137 21592054
  90. [109]Kummer MP Heneka MT PPARs in Alzheimer’s disease PPAR Res 2008 2008 403896 18645613 PMC2465016
  91. [110]Kersten S Peroxisome proliferator activated receptors and lipoprotein metabolism PPAR Res 2007 2008 132960 18288277 PMC2220040
  92. [111]Bensinger SJ Tontonoz P Integration of metabolism and inflammation by lipid-activated nuclear receptors Nature 2008 454 7203 470 477 18650918
  93. [112]Bookout AL Jeong Y Downes M Yu RT Evans RM Mangelsdorf DJ Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network Cell 2006 126 4 789 799 16923397 PMC6211849
  94. [113]de la Monte SM Wands JR Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer’s disease J Alzheimer Dis 2006 9 2 167 181 16873964
  95. [114]Chen YC Wu JS Tsai HD Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and neurodegenerative disorders Mol Neurobiol 2012 46 1 114 124 22434581
  96. [115]Wada K Nakajima A Katayama K Peroxisome proliferator-activated receptor γ-mediated regulation of neural stem cell proliferation and differentiation J Biol Chem 2006 281 18 12673 12681 16524877
  97. [116]Bright JJ Kanakasabai S Chearwae W Chakraborty S PPAR regulation of inflammatory signaling in CNS diseases PPAR Res 2008 2008 658520 18670616 PMC2490815
  98. [118]Landreth G Therapeutic use of agonists of the nuclear receptor PPAR in Alzheimers disease Curr Alzheimer Res 2007 4 2 159 164 17430241
  99. [119]Neumann KF Rojo L Navarrete LP Farías G Reyes P Maccioni RB Insulin resistance and Alzheimer’s disease: molecular links clinical implications Curr Alzheimer Res 2008 5 5 438 447 18855585
  100. [120]Jiang Q Heneka M Landreth GE The role of peroxisome proliferator-activated receptor-γ PPARγ) in Alzheimer’s disease CNS Drugs 2008 22 1 1 14 18072811
  101. [121]Zolezzi JM Silva-Alvarez C Ordenes D Peroxisome proliferator-activated receptor (PPAR) gamma and PPAR alpha agonists modulate mitochondrial fusion-fission dynamics: relevance to reactive oxygen species (ROS)-related neurodegenerative disorders? PLoS One 2013 8 5 e64019 23675519 PMC3652852
  102. [122]Heneka MT Sastre M Dumitrescu-Ozimek L Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice Brain 2005 128 6 1442 1453 15817521
  103. [123]Gray E Ginty M Kemp K Scolding N Wilkins A The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function J Neuroinflammation 2012 5 9 PMC3368767 22480361
  104. [124]d’Abramo C Ricciarelli R Pronzato MA Davies P Troglitazone, a peroxisome proliferator-activated receptor-γ agonist, decreases tau phosphorylation in CHOtau4R cells J Neurochem 2006 98 4 1068 1077 16787414
  105. [125]Wang G Namura S Effects of chronic systemic treatment with peroxisome proliferator-activated receptor alpha activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice Neurosci Res 2011 70 2 230 237 21300114 PMC3092009
  106. [126]Schnegg CI Kooshki M Hsu F-C Sui G Robbins ME PPAR delta prevents radiation-induced proinflammatory responses in microglia via transrepression of NF-kappa B and inhibition of the PK alpha/MEK1/2/ERK1/2/AP-1 pathway Free Radic Biol Med 2012 52 9 1734 1743 22387176 PMC3341532
  107. [127]Barroso E del Valle J Porquet D Tau hyperphosphorylation and increased BACE1 and RAGE levels in the cortex of PPAR beta/delta-null mice Biochim Biophys Acta 2013 1832 8 1241 1248 23507144
  108. [129]Swardfager W Lanctôt K Rothenburg L Wong A Cappell J Herrmann N A meta-analysis of cytokines in Alzheimer’s disease Biol Psychiatry 2010 68 10 930 941 20692646
  109. [130]Gezen-Ak D Dursun E Hanağası H BDNF, TNF alpha, HSP90, CFH, and IL-10 serum levels in patients with early or late onset Alzheimer’s disease or mild cognitive impairment J Alzheimers Dis 2013 37 1 185 195 23948885
  110. [131]McAlpine FE Lee JK Harms AS Inhibition of soluble TNF signaling in a mouse model of Alzheimer’s disease prevents pre-plaque amyloid-associated neuropathology Neurobiol Dis 2009 34 1 163 177 19320056 PMC2948857
  111. [134]Tweedie D Ferguson RA Fishman K Tumor necrosis factor-alpha synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease J Neuroinflammation 2012 29 9 PMC3405480 22642825
  112. [135]Uslu S Akarkarasu ZE Ozbabalik D Levels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer’s disease and vascular dementia Neurochem Res 2012 37 7 1554 1559 22437436
  113. [136]Kornman KS Interleukin 1 genetics, inflammatory mechanisms, and nutrigenetic opportunities to modulate diseases of aging Am J Clin Nutr 2006 83 2 475S 483S 16470016
  114. [137]Honma T Hatta K Hitomi Y Increased systemic inflammatory interleukin-1 beta and interleukin-6 during agitation as predictors of Alzheimer’s disease Int J Geriatr Psychiatry 2013 28 3 233 241 22535710
  115. [138]Payão SL Gonçalves GM de Labio RW Association of interleukin 1 beta polymorphisms and haplotypes with Alzheimer’s disease J Neuroimmunol 2012 247 1–2 59 62 22498095
  116. [140]Liu L Aboud O Jones RA Mrak RE Griffin S Barger SW Apolipoprotein E expression is elevated by interleukin 1 and other interleukin 1-induced factors J Neuroinflammation 2011 8 175 22171672 PMC3286434
  117. [141]Sheng JG Jones RA Zhou XQ Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer’s disease: potential significance for tau protein phosphorylation Neurochem Int 2001 39 5 341 348 11578769 PMC3833633
  118. [142]Griffin WST Liu L Li Y Mrak RE Barger SW Interleukin-1 mediates Alzheimer and Lewy body pathologies J Neuroinflammation 2006 3 1 5 16542445 PMC1435743
  119. [143]Ghosh S Wu MD Shaftel SS Sustained interleukin-1 beta overexpression exacerbates tau pathology despite reduced Amyloid burden in an Alzheimer’s mouse model J Neurosci 2013 33 11 5053 5064 23486975 PMC3637949
  120. [144]Hein AM Stutzman DL Bland ST Prostaglandins are necessary and sufficient to induce contextual fear learning impairments after interleukin-1 beta injections into the dorsal hippocampus Neuroscience 2007 150 4 754 763 18035502 PMC2246066
  121. [145]Hein AM Stasko MR Matousek SB Sustained hippocampal IL-1β overexpression impairs contextual and spatial memory in transgenic mice Brain Behav Immun 2010 24 2 243 253 19825412 PMC2818290
  122. [147]Erta M Quintana A Hidalgo J Interleukin-6, a major cytokine in the central nervous system Int J Biol Sci 2012 8 9 1254 1266 23136554 PMC3491449
  123. [148]Serretti A Olgiati P De Ronchi D Genetics of Alzheimer’s disease. A rapidly evolving field J Alzheimer Dis 2007 12 1 73 92 17851196
  124. [149]Chen SY Chen TF Lai LC Sequence variants of interleukin 6 (IL-6) are significantly associated with a decreased risk of late-onset Alzheimer’s disease J Neuroinflammation 2012 24 9 PMC3315433 22272811
  125. [150]Qi H-P Qu Z-Y Duan S-R Wei S-Q Wen S-R Bi S IL-6-174 G/C and-572 C/G polymorphisms and risk of Alzheimer’s disease PLoS One 2012 7 6 e37858 22701584 PMC3368923
  126. [151]Querfurth HW LaFerla FM Mechanisms of disease N Engl J Med 2010 362 4 329 344 20107219
  127. [152]Quintanilla RA Orellana DI González-Billault C Maccioni RB Interleukin-6 induces Alzheimer-type phosphorylation of tau protein by deregulating the cdk5/p35 pathway Exp Cell Res 2004 295 1 245 257 15051507
  128. [153]Hua Y Guo X Huang Q Kong Y Lu X Association between interleukin-6-174G/C polymorphism and the risk of Alzheimer’s disease: a meta-analysis Int J Neurosci 2013 123 9 626 635 23510010
  129. [154]Szczepanik AM Funes S Petko W Ringheim GE IL-4, IL-10 and IL-13 modulate Aβ (1–42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line J Neuroimmunol 2001 113 1 49 62 11137576
  130. [155]Town T Laouar Y Pittenger C Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology Nat Med 2008 14 6 681 687 18516051 PMC2649699
  131. [156]Kim J Onstead L Randle S Abeta40 inhibits amyloid deposition in vivo J Neurosci 2007 27 3 627 633 17234594 PMC6672801
  132. [158]Dobolyi A Vincze C Pal G Lovas G The neuroprotective functions of transforming growth factor beta proteins Int J Mol Sci 2012 13 7 8219 8258 22942700 PMC3430231
  133. [159]Rota E Bellone G Rocca P Bergamasco B Emanuelli G Ferrero P Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients Neurol Sci 2006 27 1 33 39 16688597
  134. [160]Motta M Imbesi R Di Rosa M Stivala F Malaguarnera L Altered plasma cytokine levels in Alzheimer’s disease: correlation with the disease progression Immunol Lett 2007 114 1 46 51 17949824
  135. [161]Morimoto K Horio J Satoh H Expression profiles of cytokines in the brains of Alzheimer’s disease (AD) patients compared to the brains of non-demented patients with and without increasing AD pathology J Alzheimer Dis 2011 25 1 59 76 PMC3572941 21368376
  136. [162]Lifshitz V Weiss R Benromano T Immunotherapy of cerebrovascular amyloidosis in a transgenic mouse model Neurobiol Aging 2012 33 2 e431 e432 PMC3136542 21371785
  137. [163]Huang L Jia J Liu R Decreased serum levels of the angiogenic factors VEGF and TGF-beta1 in Alzheimer’s disease and amnestic mild cognitive impairment Neurosci Lett 2013 550 60 63 23827227
  138. [164]Mocali A Cedrola S Della Malva N Increased plasma levels of soluble CD40, together with the decrease of TGFβ1, as possible differential markers of Alzheimer disease Exp Gerontol 2004 39 10 1555 1561 15501026
  139. [166]Caraci F Spampinato S Sortino MA Dysfunction of TGF-β1 signaling in Alzheimer’s disease: perspectives for neuroprotection Cell Tissue Res 2012 347 1 291 301 21879289
  140. [167]Ma D Doi Y Jin S TGF-beta induced by interleukin-34-stimulated microglia regulates microglial proliferation and attenuates oligomeric amyloid beta neurotoxicity Neurosci Lett 2012 529 1 86 91 22985514
  141. [168]Tichauer JE von Bernhardi R Transforming growth factor-beta stimulates beta amyloid uptake by microglia through Smad3-dependent mechanisms J Neurosci Res 2012 90 10 1970 1980 22715062
  142. [169]Weiss R Lifshitz V Frenkel D TGF-β1 affects endothelial cell interaction with macrophages and T-cells leading to the development of cerebrovascular amyloidosis Brain Behav Immun 2011 25 5 1017 1024 21112386
  143. [170]Martinez-Canabal A Wheeler AL Sarkis D Chronic over-expression of TGF beta 1 alters hippocampal structure and causes learning deficits Hippocampus 2013 23 12 1198 1211 23804429
  144. [172]De Strooper B Vassar R Golde T The secretases: enzymes with therapeutic potential in Alzheimer disease Nat Rev Neurol 2010 6 2 99 107 20139999 PMC2879045
  145. [173]Thal DR von Arnim C Griffin WS Pathology of clinical and preclinical Alzheimer’s disease Eur Arch Psychiatry Clin Neurosci 2013 263 S137 S145 24077890
  146. [174]Palop JJ Mucke L Amyloid-[beta]-induced neuronal dysfunction in Alzheimer’s disease: from synapses toward neural networks Nat Neurosci 2010 13 7 812 818 20581818 PMC3072750
  147. [175]Vincent AJ Gasperini R Foa L Small DH Astrocytes in Alzheimer’s disease: emerging roles in calcium dysregulation and synaptic plasticity J Alzheimers Dis 2010 22 3 699 714 20847426
  148. [176]Carrillo-Mora P Luna R Colin-Barenque L Amyloid beta: multiple mechanisms of toxicity and only some protective effects? Oxid Med Cell Longev 2014 2014 795375 24683437 PMC3941171
  149. [177]Zotova E Bharambe V Cheaveau M Inflammatory components in human Alzheimer’s disease and after active amyloid-beta(42) immunization Brain 2013 136 2677 2696 23943781
  150. [178]Joseph-Mathurin N Dorieux O Trouche SG Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds Neurobiol Aging 2013 34 11 2613 2622 23796662 PMC4107237
  151. [179]Panza F Logroscino G Imbimbo BP Solfrizzi V Is there still any hope for amyloid-based immunotherapy for Alzheimer’s disease? Curr Opin Psychiatry 2014 27 2 128 137 24445401
  152. [180]Cohen TJ Guo JL Hurtado DE The acetylation of tau inhibits its function and promotes pathological tau aggregation Nat Commun 2011 2 252 21427723 PMC3120096
  153. [181]Iqbal K Liu F Gong C-X Grundke-Iqbal I Tau in Alzheimer disease and related tauopathies Curr Alzheimer Res 2010 7 8 656 20678074 PMC3090074
  154. [185]Arnaud L Robakis NK Figueiredo-Pereira ME It may take inflammation, phosphorylation and ubiquitination to “tangle” in Alzheimer’s disease Neurodegener Dis 2006 3 6 313 319 16954650
  155. [188]Anand R Gill KD Mahdi AA Therapeutics of Alzheimer’s disease: past, present and future Neuropharmacology 2014 76 27 50 23891641

Authors
Zhang, F., & Jiang, L.
Affiliations
General Hospital of Guangzhou Military Command (CN)
Corresponding author
Jiang, LinLan
Venue
Neuropsychiatric Disease and Treatment
Publisher
Informa UK Limited
Published
2015-01
Volume
11
Pages
243
ISSN
  • 1176-6328 (ISSN-L)
  • 1178-2021
DOI
10.2147/ndt.s75546
PMC
PMC4321665
OpenAlex
W2009970240
Cited by
276
References
191
Citations by year
2026: 12 · 2025: 22 · 2024: 21 · 2023: 23 · 2022: 32 · 2021: 27 · 2020: 27 · 2019: 33 · 2018: 31 · 2017: 12 · 2016: 23 · 2015: 12 · 2014: 1
FWCI
2.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
neuroinflammation, Alzheimer's disease, amyloid plaques, neurofibrillary tangles, blood-brain barrier dysfunction, microglia, astrocytes, MAPK signaling, NF-κB, PPARγ, cytokines, inflammatory signaling

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review